Montpellier, France

Mireille Cavaleyra

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Institut De Recherche Pour Le Developpement (Ird). Active years: 2013.

USPTO Granted Patents = 1 


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mireille Cavaleyra: Innovator in Nucleic Acid Constructions

Introduction

Mireille Cavaleyra is a notable inventor based in Montpellier, France. She has made significant contributions to the field of molecular biology, particularly in the development of nucleic acid constructions. Her work focuses on the coding of immunogenic proteins, which has important implications for medical research and treatment.

Latest Patents

Mireille Cavaleyra holds 1 patent related to her innovative work. The patent involves nucleic acid constructions that comprise isolated nucleic acids capable of coding for immunogenic proteins of promastigotes or amastigotes. These nucleic acids correspond to specific sequences and are designed for the over-expression of genes coding for excretion/secretion antigens.

Career Highlights

Throughout her career, Mireille has been associated with prestigious research institutions. She has worked at the Institut de Recherche pour le Développement (IRD), where she has contributed to various research projects aimed at advancing scientific knowledge in her field.

Collaborations

Mireille has collaborated with esteemed colleagues, including Jean-Loup Lemesre and Denis Sereno. These partnerships have enriched her research and expanded the impact of her inventions.

Conclusion

Mireille Cavaleyra's innovative work in nucleic acid constructions highlights her significant role in advancing molecular biology. Her contributions continue to influence research and development in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…